Is Pediatrix Medical Stock Outperforming Its Rivals?
With Pediatrix Medical surging 24% in a Day, it makes sense to re-evaluate vs its peers. Consistently assessing alternatives is core to a sound investment approach. Here is how Pediatrix Medical (MD) stock stacks up against its peers in size, valuation, growth and margin.
- MD has the highest operating margin among peers at 12.2%.
- MD’s revenue growth of -4.2% in the last 12 months is negative, lagging ADUS, USPH, OMI, SLP but outpacing CCRN.
- MD gained 38.6% in the past year and trades at a PE of 11.0, outperforming its peers.
As a quick background, Pediatrix Medical provides newborn, maternal-fetal, pediatric cardiology, and various pediatric subspecialty care services across the United States and Puerto Rico through a network of about 2,700 physicians.
A single stock can be risky, but there is a huge value to a broader, diversified approach. Strategic asset allocation and diversification help you stay invested. Did you know investors who panicked out of the S&P in 2020 lost significant upside that followed? Trefis High Quality Portfolio and Empirical Asset Management’s asset allocation approach are designed to reduce volatility so you can stay the course.
| MD | ADUS | USPH | OMI | CCRN | SLP | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 1.8 | 2.1 | 1.3 | 0.3 | 0.4 | 0.3 |
| Revenue ($ Bil) | 1.9 | 1.3 | 0.7 | 12.7 | 1.2 | 0.1 |
| PE Ratio | 11.0 | 25.9 | 39.6 | -0.2 | -47.9 | -5.4 |
| LTM Revenue Growth | -4.2% | 14.3% | 16.2% | 92.4% | -24.3% | 20.0% |
| LTM Operating Margin | 12.2% | 9.1% | 9.7% | 2.6% | 0.9% | 5.8% |
| LTM FCF Margin | 14.2% | 7.4% | 8.3% | -2.8% | 2.9% | 13.1% |
| 12M Market Return | 38.6% | -5.8% | 9.2% | -74.2% | 8.6% | -39.0% |
Why does this matter? MD just went up 24.2% in a day – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell MD Stock to see if Pediatrix Medical holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through MD Dip Buyer Analysis lens.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MD | -4.2% | 0.9% | 1.1% | 3.2% |
| ADUS | 14.3% | 9.1% | 11.3% | 10.0% |
| USPH | 16.2% | 11.0% | 9.3% | 11.7% |
| OMI | 92.4% | 3.6% | 3.8% | 1.7% |
| CCRN | -24.3% | -33.5% | -28.0% | 67.2% |
| SLP | 20.0% | 17.5% | 10.5% | 16.0% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MD | 12.2% | 9.1% | 7.9% | 10.1% |
| ADUS | 9.1% | 8.9% | 8.6% | 7.2% |
| USPH | 9.7% | 9.8% | 11.6% | 11.9% |
| OMI | 2.6% | 2.8% | 2.9% | 2.8% |
| CCRN | 0.9% | 1.7% | 6.5% | 10.3% |
| SLP | 5.8% | 8.8% | 14.6% | 27.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MD | 11.0 | -11.0 | -12.7 | 18.7 |
| ADUS | 25.9 | 29.0 | 23.8 | 34.3 |
| USPH | 39.6 | 50.5 | 90.1 | 37.2 |
| OMI | -0.2 | -2.8 | -35.4 | 65.0 |
| CCRN | -47.9 | -41.6 | 11.0 | 5.3 |
| SLP | -5.4 | 56.0 | 90.2 | 59.2 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.